LCM
EPIX

Lynwood Capital Management’s ESSA Pharma EPIX Stock Holding History

Lynwood Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57,181
Closed -$812K – 141
2021
Q4 		$812K Buy
+57,181
New +$637K 0.78% 44

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Lynwood Capital Management's EPIX Position: Q1 2022 in Review

Lynwood Capital Management sold out of ESSA Pharma (EPIX) in Q1 2022, closing a stake of 57,181 shares — an estimated $812K sold.

Lynwood Capital Management first reported a position in EPIX in Q4 2021 and held it in 1 quarter. The position peaked at $812K in Q4 2021. 70 funds tracked by Wall St. Rank hold EPIX as of Q1 2022.

  • Lynwood Capital Management reported no remaining ESSA Pharma position as of Q1 2022 after selling out during the quarter.
  • Lynwood Capital Management sold 57,181 ESSA Pharma shares in Q1 2022, an estimated $812K.
  • Lynwood Capital Management first reported a position in ESSA Pharma in Q4 2021 and held it in 1 quarter.
  • Lynwood Capital Management's ESSA Pharma position peaked at $812K in Q4 2021.
  • 70 funds tracked by Wall St. Rank held ESSA Pharma as of Q1 2022.

Based on Lynwood Capital Management's 13F filing for Q1 2022, filed 5 May 2022.